Could everyday heart drugs shield cancer patients from Radiation's cardiac toll?

NCT ID NCT07685938

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This study tests whether two common heart medications—atorvastatin (a statin) and lisinopril (an ACE inhibitor)—can prevent or reduce heart damage caused by radiation therapy for chest cancers like breast, lung, and esophageal cancer. About 60 adults receiving chest radiation will take either the drug combination or a placebo daily during radiation and for six months after. The goal is to see if these drugs help maintain blood flow to the heart, measured by PET scans, potentially offering a simple way to protect the heart in cancer survivors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Atorvastatin and Lisinopril
What this could lead to
If it works, this could provide a simple, generic drug strategy to protect the heart in cancer patients undergoing chest radiation.
What could go wrong
This is a phase 2 trial with only 60 participants, so results may not be conclusive. The drugs may not reduce heart damage, and side effects like low blood pressure or muscle pain are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill

    Chapel Hill, North Carolina, 27599, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.